Advertisement
American Journal of Kidney Diseases

AJKD on the Move

  • Harold I. Feldman
    Correspondence
    Address correspondence to Harold I. Feldman, MD, MSCE, Department of Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Blockley Hall Rm 824, 423 Guardian Dr, Philadelphia, Pennsylvania, PA 19104.
    Affiliations
    University of Pennsylvania, Philadelphia, Pennsylvania
    Search for articles by this author
  • on behalf of thenew AJKD team
      This first issue of the year marks the journal’s move from its home base in Boston to one in Philadelphia—from one city of foundational American ideas to another—a journey also undertaken by the great inventor, editor, and University of Pennsylvania (“Penn”) icon pictured on our cover. In a similar spirit of continuity and innovation, I write to introduce myself, to acquaint readers with our broader team—which includes many new editors, some established in Philadelphia, and others who bring perspectives from around North America and the world—and to signal some of the new priorities and goals of AJKD.
      I come to the Editor-in-Chief role after more than 3 decades of work that integrates nephrology and epidemiology. My research across the spectrum of chronic kidney disease and end-stage kidney disease, as well as my years as a clinical nephrologist, have deeply motivated me to take on this new role, promoting and disseminating the highest quality scholarship and educational materials for the renal medicine community. My current and past leadership roles in national research programs such as the CRIC (Chronic Renal Insufficiency Cohort) Study, the Chronic Kidney Disease Biomarkers Consortium, and the Dialysis Access Consortium have helped me appreciate the role that specialized journals such as AJKD play: they enhance the quality of research and help leverage it to improve care for patients.
      Our editorial headquarters is at Penn’s Perelman School of Medicine, an environment in which the highest forms of scholarship are promoted and celebrated. I lead its Department of Biostatistics and Epidemiology and Center for Clinical Epidemiology and Biostatistics, and I am deeply honored to be joined at AJKD by 2 Penn-based Deputy Editors, Jeffrey Berns, MD, and Laura Dember, MD, who have had long and productive careers conducting and championing clinical research in nephrology in addition to their deep experience as clinical nephrologists.
      We are joined by an equally extraordinary and committed set of colleagues:
      • Associate Editors (equivalent to “Co-Editors” in the previous editorial team): Roy Bloom, MD; Sue Furth, MD, PhD; Charmaine Lok, MD; Jim Kaufman, MD; and Peter Reese, MD, MSCE
      • Education Editor: Stan Goldfarb, MD
      • International Editors: Gavin Becker, MD, FRACP; Magdalena Madero, MD; and Maarten Taal, MBChB, MMed, MD, FCP(SA), FRCP
      • Health Equity Editor: Carmen Peralta, MD, MAS
      • Pathology Editor: Matthew Palmer, MD
      • Statistics/Methods Editors: Jesse Hsu, PhD; Chris Schmid, PhD; and Peter Yang, PhD
      • Social Media Editor: Tim Yau, MD
      • Atlas of Renal Pathology II Editor: Agnes B. Fogo, MD
      • Core Curriculum in Nephrology Editor: Asghar Rastegar, MD
      • In a Few Words Editor: Dena Rifkin, MD, MS
      • In Practice Editor: Holly Kramer, MD, MPH
      • Policy Forum Editor: Dan Weiner, MD, MS
      • Teaching Case Editor: Jerry Yee, MD
      Beyond these physician editors—who will work closely with Jeff, Laura, and me to craft the content of each issue—we are supported by an editorial office staff with a collective quarter century of AJKD experience: Nijsje Dorman, who has expertly managed AJKD over the past decade, Alina Foo, Elizabeth Frank, Barbara Saper, and Noah Skaroff. We would be remiss if we did not also recognize Dr Kerry Willis and her team at the National Kidney Foundation, as well as our Executive Publisher, Livia Berardi, at Elsevier; their wise counsel has been essential as we prepare to take over the journal from the very able hands of Dr Andrew Levey, who published his last issue as Editor-in-Chief last month.
      On behalf of us all, I thank Andy Levey and his Tufts Medical Center–based team for the strong foundation from which we launch our efforts. Under their leadership, AJKD has been recognized internationally as a leading source of information on clinical nephrology practice and clinical research. We plan to continue to reflect patient priorities in the journal’s content and will endeavor to expand AJKD’s coverage on patient-centered outcomes.
      In addition, our upcoming Policy Forum series will cover a broad array of topics, including the economics of, access to, and disparities in health care for renal disease. We will also increase our coverage of pediatric nephrology and transplantation, and readers will note our concerted effort to include more work by authors from Europe, Africa, Asia, and Latin America. This greater international focus will enable us to broaden our content and to further connect to audiences outside of North America. In addition, we look forward to expanding our social media presence, addressing an important need among physicians and among our younger colleagues, in particular, who, more and more, access scholarly information and discuss all facets of renal medicine via mobile devices.
      More than 30 years ago, I was drawn to the field of nephrology because of its highly analytical nature, its rapidly evolving technologies, and its relevance to a vast array of the world’s population. This love of the field is no less important today: it underlies everything my colleagues and I do as an editorial team. Over the next 5 years, we anticipate that our field will continue to evolve, and we are deeply committed to critically examining these changes in ways that resonate with the needs of our readers. We are honored and humbled to be entrusted with this challenge as we embark on this journey with you all.

      Acknowledgements

      Financial Disclosure: Dr Feldman receives support from the National Kidney Foundation in furtherance of his duties as AJKD Editor-in-Chief.